GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cantargia AB (OSTO:CANTA) » Definitions » Cyclically Adjusted Price-to-FCF

Cantargia AB (OSTO:CANTA) Cyclically Adjusted Price-to-FCF : (As of Jun. 29, 2025)


View and export this data going back to 2015. Start your Free Trial

What is Cantargia AB Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Cantargia AB Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Cantargia AB's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cantargia AB Cyclically Adjusted Price-to-FCF Chart

Cantargia AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Cantargia AB Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Cantargia AB's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, Cantargia AB's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cantargia AB's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cantargia AB's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Cantargia AB's Cyclically Adjusted Price-to-FCF falls into.


;
;

Cantargia AB Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Cantargia AB's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, Cantargia AB's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2025 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=-0.136/132.8245*132.8245
=-0.136

Current CPI (Mar. 2025) = 132.8245.

Cantargia AB Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201506 -0.280 99.995 -0.372
201509 -0.244 100.228 -0.323
201512 -0.201 100.276 -0.266
201603 -0.368 100.751 -0.485
201606 -0.325 101.019 -0.427
201609 -0.450 101.138 -0.591
201612 -0.733 102.022 -0.954
201703 -0.523 102.022 -0.681
201706 -0.449 102.752 -0.580
201709 -0.365 103.279 -0.469
201712 0.187 103.793 0.239
201803 -0.385 103.962 -0.492
201806 -0.354 104.875 -0.448
201809 -0.276 105.679 -0.347
201812 -0.301 105.912 -0.377
201903 -0.176 105.886 -0.221
201906 -0.363 106.742 -0.452
201909 -0.316 107.214 -0.391
201912 -0.432 107.766 -0.532
202003 -0.408 106.563 -0.509
202006 -0.351 107.498 -0.434
202009 -0.388 107.635 -0.479
202012 -0.396 108.296 -0.486
202103 -0.509 108.360 -0.624
202106 -0.567 108.928 -0.691
202109 -0.943 110.338 -1.135
202112 -0.748 112.486 -0.883
202203 -1.205 114.825 -1.394
202206 -0.951 118.384 -1.067
202209 -0.562 122.296 -0.610
202212 -0.369 126.365 -0.388
202303 -0.447 127.042 -0.467
202306 -0.419 129.407 -0.430
202309 -0.513 130.224 -0.523
202312 -0.317 131.912 -0.319
202403 -0.299 132.205 -0.300
202406 -0.202 132.716 -0.202
202409 -0.242 132.304 -0.243
202412 -0.143 132.987 -0.143
202503 -0.136 132.825 -0.136

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Cantargia AB  (OSTO:CANTA) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Cantargia AB Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Cantargia AB's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Cantargia AB Business Description

Industry
Traded in Other Exchanges
Address
Scheelevagen 27, Lund, SWE, 223 63
Cantargia AB is a Swedish biotech company that develops targeted antibody-based drugs for cancer as well as autoimmune and inflammatory diseases. It has developed specific antibodies against IL1RAP to treat serious, life-threatening diseases. The company's development programme includes the candidate drugs nadunolimab (CAN04) and CAN10, both in the clinical development stage, as well as its antibody platform CANxx.

Cantargia AB Headlines

No Headlines